These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 21216464)

  • 1. Generation of antigen-specific cytotoxic T lymphocytes using a leukemic plasmacytoid dendritic cell line as antigen presenting cells.
    Yamahira A; Narita M; Nakamura T; Watanabe N; Kaji M; Taniguchi T; Hashimoto S; Furukawa T; Toba K; Aizawa Y; Kuzushima K; Takahashi M
    Leuk Res; 2011 Jun; 35(6):793-9. PubMed ID: 21216464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of the antigen-specific cytotoxic T lymphocyte-inducing ability in the PMDC11 leukemic plasmacytoid dendritic cell line via lentiviral vector-mediated transduction of the caTLR4 gene.
    Iwabuchi M; Narita M; Uchiyama T; Iwaya S; Oiwa E; Nishizawa Y; Hashimoto S; Bonehill A; Kasahara N; Takizawa J; Takahashi M
    Mol Med Rep; 2015 Aug; 12(2):2443-50. PubMed ID: 25936433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of antigen presenting ability in the leukemic plasmacytoid dendritic cell line (PMDC05) by lentiviral vector-mediated transduction of CD80 gene.
    Yamahira A; Narita M; Ishii K; Jayathilake RM; Iwabuchi M; Satoh N; Uchiyama T; Taniguchi T; Hashimoto S; Kasahara N; Faure E; Bogan B; Takizawa J; Sone H; Takahashi M
    Leuk Res; 2012 Dec; 36(12):1541-6. PubMed ID: 23040531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
    Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A leukemic plasmacytoid dendritic cell line, PMDC05, with the ability to secrete IFN-alpha by stimulation via Toll-like receptors and present antigens to naïve T cells.
    Narita M; Watanabe N; Yamahira A; Hashimoto S; Tochiki N; Saitoh A; Kaji M; Nakamura T; Furukawa T; Toba K; Fuse I; Aizawa Y; Takahashi M
    Leuk Res; 2009 Sep; 33(9):1224-32. PubMed ID: 19443030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of antigen-specific cytotoxic T lymphocytes by fusion cells generated from allogeneic plasmacytoid dendritic and tumor cells.
    Koido S; Homma S; Kan S; Takakura K; Namiki Y; Kobayashi H; Ito Z; Uchiyama K; Kajihara M; Arihiro S; Arakawa H; Okamoto M; Ohkusa T; Gong J; Tajiri H
    Int J Oncol; 2014 Jul; 45(1):470-8. PubMed ID: 24819411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered Fas-mediated apoptosis.
    Chattergoon MA; Kim JJ; Yang JS; Robinson TM; Lee DJ; Dentchev T; Wilson DM; Ayyavoo V; Weiner DB
    Nat Biotechnol; 2000 Sep; 18(9):974-9. PubMed ID: 10973219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function.
    Filaci G; Fravega M; Negrini S; Procopio F; Fenoglio D; Rizzi M; Brenci S; Contini P; Olive D; Ghio M; Setti M; Accolla RS; Puppo F; Indiveri F
    Hum Immunol; 2004 Feb; 65(2):142-56. PubMed ID: 14969769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Robust expansion of viral antigen-specific CD4+ and CD8+ T cells for adoptive T cell therapy using gene-modified activated T cells as antigen presenting cells.
    Melenhorst JJ; Solomon SR; Shenoy A; Hensel NF; McCoy JP; Keyvanfar K; Barrett AJ
    J Immunother; 2006; 29(4):436-43; discussion 365-6. PubMed ID: 16799339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mature dendritic cells are superior to immature dendritic cells in expanding antigen-specific naive and memory CD8+ T cells.
    Tomiyama M; Takahara M; Egawa K; Nieda M
    Anticancer Res; 2004; 24(5C):3327-33. PubMed ID: 15515428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of cytotoxic T lymphocytes by dendritic cells pulsed with murine leukemic cell RNA.
    Jung CW; Kwon JH; Seol JG; Park WH; Hyun JM; Kim ES; Kim ST; Lee SJ; Kim BK; Lee YY
    Am J Hematol; 2004 Mar; 75(3):121-7. PubMed ID: 14978690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus-specific cytolytic T-cell lines and clones generated against adenovirus-pp65-infected dendritic cells.
    Keever-Taylor CA; Margolis D; Konings S; Sandford GR; Nicolette CA; Lawendowski C; Burns WH
    Biol Blood Marrow Transplant; 2001; 7(5):247-56. PubMed ID: 11400946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
    Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cells stimulate the expansion of PML-RAR alpha specific cytotoxic T-lymphocytes: its applicability for antileukemia immunotherapy.
    Osman Y; Takahashi M; Zheng Z; Toba K; Liu A; Furukawa T; Narita M; Aizawa Y; Koike T; Shibata A
    J Exp Clin Cancer Res; 1999 Dec; 18(4):485-92. PubMed ID: 10746975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
    Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
    Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.
    Hammer MH; Brestrich G; Mittenzweig A; Roemhild A; Zwinger S; Subklewe M; Beier C; Kurtz A; Babel N; Volk HD; Reinke P
    J Immunother; 2007; 30(8):817-24. PubMed ID: 18049333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.
    Obermann S; Petrykowska S; Manns MP; Korangy F; Greten TF
    Immunology; 2007 Sep; 122(1):90-7. PubMed ID: 17472719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD11c+ blood dendritic cells induce antigen-specific cytotoxic T lymphocytes with similar efficiency compared to monocyte-derived dendritic cells despite higher levels of MHC class I expression.
    Radford KJ; Turtle CJ; Kassianos AJ; Hart DN
    J Immunother; 2006; 29(6):596-605. PubMed ID: 17063122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12.
    Foster AE; Leen AM; Lee T; Okamura T; Lu A; Vera J; Atkinson R; Bollard CM; Dotti G; Rooney CM
    J Immunother; 2007; 30(5):506-16. PubMed ID: 17589291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.